Department of Pediatrics, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Xiqing.
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Xiqing, Tianjin, China.
Medicine (Baltimore). 2021 Mar 12;100(10):e25134. doi: 10.1097/MD.0000000000025134.
Epilepsy is 1 of the common neurodevelopmental diseases. It can affect about 0.5% to 1.0% of the population regardless of their race and social class. Despite the development of a wide range of treatments, there remaining about one-third of patients still experience seizures. Chinese herbal compounds containing scorpion (CHCCS) have shown an outstanding curative effect on nerve protection and epilepsy. But there's no study to assess its clinical efficacy and safety.
Each data of CHCCS in treating epilepsy from related English and Chinese databases will be searched. The primary outcome is the efficacy of the CHCCS on epilepsy. And the secondary outcomes include recurrence rate and side effects. The risk of bias will be assessed, and RevMan5.3 and Stata14.0 will be performed for meta-analysis. Finally, we will assess the level of the resulting evidence.
The results of the study will be combined with current evidence and published in a peer-reviewed journal.
This study will specifically investigate the effectiveness and safety of CHCCS in treating epilepsy.
INPLASY202120056.
癫痫是常见的神经发育性疾病之一。无论种族和社会阶层如何，其发病率约为 0.5%至 1.0%。尽管有广泛的治疗方法发展，但仍有大约三分之一的患者仍存在癫痫发作。含有蝎子的中药复方（CHCCS）在神经保护和癫痫治疗方面显示出显著的疗效。但目前尚无研究评估其临床疗效和安全性。
从相关的英文和中文数据库中搜索 CHCCS 治疗癫痫的每一项数据。主要结局是 CHCCS 对癫痫的疗效。次要结局包括复发率和副作用。将评估偏倚风险，并使用 RevMan5.3 和 Stata14.0 进行荟萃分析。最后，我们将评估结果证据的水平。
研究结果将结合现有证据，并发表在同行评议的期刊上。
本研究将专门调查 CHCCS 治疗癫痫的有效性和安全性。
INPLASY 注册号：INPLASY202120056。
